The Impact of Duration of Treatment on Reported Time-to-Onset in Spontaneous Reporting Systems for Pharmacovigilance

Open Access

Peer-reviewed

Research Article

Ghazaleh Karimi ,

* E-mail: ghazaleh.karimi@who-umc.org

Affiliation Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
⨯
Kristina Star,

Affiliations Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
⨯
G. Niklas Norén,

Affiliations Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, Department of Mathematics, Stockholm University, Stockholm, Sweden
⨯
Staffan Hägg

Affiliation Department of Drug Research/Clinical Pharmacology, Linköping University, Linköping, Sweden
⨯

Reader Comments (0)

Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Adverse reactions
Is the Subject Area "Adverse reactions" applicable to this article?

Thanks for your feedback.
ACE inhibitor therapy
Is the Subject Area "ACE inhibitor therapy" applicable to this article?

Thanks for your feedback.
NSAIDs
Is the Subject Area "NSAIDs" applicable to this article?

Thanks for your feedback.
Therapeutic drug monitoring
Is the Subject Area "Therapeutic drug monitoring" applicable to this article?

Thanks for your feedback.
Drug safety
Is the Subject Area "Drug safety" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Hepatitis
Is the Subject Area "Hepatitis" applicable to this article?

Thanks for your feedback.